CD55/DAF Antibody (MEM-118)

Avoidance by host tissues of attack by autologous complement proteins is dependent in part on the activities of membrane regulatory factors. One molecule involved in this control is a 70 kD glycoprotein termed decay-accelerating factor (DAF), or CD55. Interruption by CD55 of the complement sequence at an early step in activation effectively halts progression of the cascade and prevents consequent cell injury. In man, CD55 is expressed on the plasma membrane of all cell types that are in intimate contact with plasma complement proteins. This protein recognizes C4b and C3b fragments that condense with cell-surface hydroxyl or amino groups when nascent C4b and C3b are locally generated during C4 and c3 activation. Interaction of daf with cell-associated C4b and C3b polypeptides interferes with their ability to catalyze the conversion of C2 and factor B to enzymatically active C2a and Bb and thereby prevents the formation of C4b2a and C3bBb, the amplification convertases of the complement cascade. CD55 also acts as the receptor for echovirus 7 and related viruses(echoviruses 13, 21, 29 and 33). It is attached to the membrane by a GPI-anchor.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Array NB500-395

• CD55/DAF Antibodies
• CD55/DAF Antibody Pairs
• CD55/DAF ELISA Kit
• CD55/DAF Lysate
• CD55/DAF Proteins
• CD55/DAF Proteins and Enzymes